June 19, 2021
Pharmabiz
Kite partners with Shoreline Biosciences to develop novel allogeneic cell therapies
Kite, a Gilead company, and Shoreline Biosciences, a biotechnology company, announced a strategic par... See more »
1,159 Followers on Owler
Kite Pharma
Kite Pharma is a biotechnology company that discovers and develops cell-based immunotherapies for the treatment of cancer. Read more
CEO
Christi L. Shaw
Est. Annual Revenue
Est. Employees
Sector
Headquarters
Missing a competitor? Contribute!
Jounce is perceived as one of Kite Pharma's biggest rivals. Jounce is headquartered in Cambridge, Massachusetts, and was founded in 2012. Like Kite Pharma, Jounce also operates in the Biotechnology industry. Jounce generates 332% the revenue of Kite Pharma.
Weigh-in!
Help the Owler community know moreTrending News for Kite Pharma and Kite Pharma's Competitors
June 18, 2021
Clinical Trials Arena
First patient dosed in BioNTech Phase II trial of mRNA cancer vaccine
The post First patient dosed in BioNTech Phase II trial of mRNA cancer vaccine appeared first on Clin... See more »
Kite Pharma Acquisitions
No recent acquisitions found related to Kite Pharma
Kite Pharma Funding History
Since Kite Pharma was founded in 2009, it has participated in 6 rounds of funding. In total Kite Pharma has raised $634.9M. Kite Pharma's last funding round was on Mar 2017 for a total of $409.7M
ROUND
FUNDING DATE
AMOUNT
INVESTORS
Post-IPO Equity
Mar 2017
$409.7M
-
IPO
Jun 2014
$127.5M
-
Since Kite Pharma was founded in 2009, it has participated in 6 rounds of funding. In total Kite Pharma has raised $634.9M. Kite Pharma's last funding round was on Mar 2017 for a total of $409.7M
Kite Pharma Investments
FOLLOW STATUS
COMPANY
DESCRIPTION
AMOUNT
INVESTMENT DATE
ROUND
EXIT DATE
Kite Pharma News
April 3, 2021Pharmabiz
Kite seeks US FDA approval for Tecartus to treat adult patients with relapsed or refractory AML
Kite, a Gilead Company announced that it has submitted a supplemental Biologics License Application (... See more »
March 29, 2021Los Angeles Business Journal
Kite Pharma's Yescarta Approved for Adult Lymphoma Treatment
Santa Monica-based Kite Pharma announced March 5 that the Food and Drug Administration has granted ac... See more »
March 16, 2021BioSpace
COTA, Inc. and Kite Collaborate To Expand the Use of Real-World Data To Drive Faster, Effective Treatments for Cancers
COTA, Inc., an oncology real-world data and analytics company, today announced a collaboration with K... See more »
March 8, 2021Benzinga
Gilead's Kite Pharma Earns FDA Nod For Yescarta For Type Of Blood Cancer
The FDA has granted accelerated approval to Gilead Sciences Inc's (NASDAQ: GILD) Kite Pharma's 'Yesca... See more »
March 8, 2021Drug Store News
Kite wins FDA OK for new indication for Yescarta
Kite's Yescarta is the first CAR T-Cell therapy approved for indolent follicular lymphoma.... See more »
February 24, 2021FinSMEs
Orna Therapeutics Raises Over $100M Funding
Orna Therapeutics, a Cambridge, Mass.-based biotechnology company dedicated to designing and deliveri... See more »
February 10, 2021MarketScreener
Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylactic Corticosteroid Use With Yescarta in Patients With Relapsed or Refractory Large B-cell lymphoma
(marketscreener.com) -- Use of Corticosteroids Prior to Yescarta Infusion Has the Potential to Impact... See more »
Kite Pharma Press Releases
December 6, 2020StreetInsider
Yescarta Shows Positive Results as a First-Line Treatment for Patients With High-Risk Large B-cell Lymphoma
-- 85 Percent of Patients Responded to a Single Infusion of Yescarta, Including 74 Percent of Patient... See more »
December 5, 2020StreetInsider
New Data for TecartusTM Demonstrate Durable Responses at One Year Follow-Up in Relapsed or Refractory Mantle Cell Lymphoma
-- Median Overall Survival Still Not Reached After Single Infusion of Tecartus in Pivotal ZUMA-2 Tria... See more »
November 5, 2020Business Wire
Gilead and Kite to Share Latest Scientific Advances in Hematologic Malignancies at ASH 2020
FOSTER CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and... See more »
October 30, 2020PR Newswire
Amarna Therapeutics Appoints Kite Pharma veteran Dr. Markwin Velders to its Supervisory Board
LEIDEN, Netherlands, Oct. 30, 2020 /PRNewswire/ -- Amarna Therapeutics, a Dutch privately held biotec... See more »
September 30, 2020PRWeb
Kite Pharma, Inc. Wins 2020 MEDA Economic Development Project Award
Kite Pharma, Inc., a Gilead Company, has been named by the Maryland Economic Development Association ... See more »
September 4, 2020centralcharts
Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Yescarta in Relapsed or Refractory Indolent Non-Hodgkin Lymphomas
Kite, a Gilead Company (Nasdaq: GILD), today announced that it has submitted a supplemental Biologics... See more »
October 23, 2019centralcharts
Humanigen updates on its clinical collaboration with Gilead Sciences subsidiary, Kite
Humanigen Inc (OTCMKTS:HGEN) CEO Cameron Durrant spoke with Proactive at the 2019 BIO Investor Forum ... See more »
Social Media
Kite Pharma Headquarters
Trending Companies
IN THE NEWS
Marvell | Danaher | Essex | KM Croatia | Pfizer | CALL OF DUTY | Optum | Turquoise Hill | ARYZTA | Mercury Systems | Hibbett | Lipocine | Cohesionmarketingpartners | HP | Keysight | Monmouth University | Xiaomi | Brookfield Asset Management | Black & Veatch | Hyundai | Vulcan Materials | Costa | Food Bazaar | Xilinx | General Dynamics | IBM | Wind River Environmental | SKS Business Services | Huawei | Coca-Cola | Ryan & Maniskas | Blink | AutoZone | Caesars Entertainment | Citi | Pathbreaker Ventures | Alabama Power | Brixmor | Airbnb | Medifast | Xandr | Avis Budget Group | Franc Environmental | Omega | NASA | ICICI Securities | Synchronous Health | AIA Chicago | Northland Rehab Supply | Escola de Inteligencia
PEOPLE ALSO VIEWED
Verily | NEB | Principia Biopharma, Inc. | Fate Therapeutics | Fedora Pharma | Lundbeck | Zymergen | Novartis | Mankind pharma | Jamp Pharma | BioLegend, Inc. | GVK BIO | Canopy Growth | NanoString | Par | The University of North Carolina at Chapel Hill | James Hardie Australia Pty. Ltd. | Canonical | Sea Limited | AutoNation | Audobon Ambulatory Surgery Center, LLC | Primex Pharmaceuticals | Tyme | DARA BioSciences | Cynata | Happy Wheels Unblocked | Rehlat | Disneyland Resort | Sarkari Result | Tax2win
Kite Pharma Summary
ABOUT
Overview
Kite Pharma is a biotechnology company that discovers and develops cell-based immunotherapies for the treatment of cancer. Kite Pharma was founded in 2009. Kite Pharma's headquarters is located in Santa Monica, California, USA 90404. It has raised 634...
CEO
Kite Pharma's CEO, Christi L. Shaw, currently has an approval rating of 81%. Kite Pharma's primary competitors are Jounce, Agenus & bluebird bio.Website
kitepharma.comFrequently Asked Questions about Kite Pharma
When was Kite Pharma founded?
Kite Pharma was founded in 2009Who is Kite Pharma's CEO?
Kite Pharma's CEO is Christi L. ShawHow much revenue does Kite Pharma generate?
Kite Pharma generates $45M in revenueHow much funding does Kite Pharma have?
Kite Pharma has historically raised $634.9M in fundingWhere is Kite Pharma's headquarters?
Kite Pharma's headquarters is in Santa Monica California, USA
How many employees does Kite Pharma have?
Kite Pharma has 2,000 employeesWhat sector does Kite Pharma operate in?
Kite Pharma is in Biotechnology, PharmaceuticalsWho are Kite Pharma's competitors?
Kite Pharma's top competitors are Jounce, Agenus, bluebird bioWho has Kite Pharma invested in?
Kite Pharma's has invested in companies such as Shoreline, Orna Therapeutics, Vineti
